In addition, studies have shown that inhibition of casein kinase 2 (CK2) may affect metabolic pathways in KRAS mutant CCA, providing a new research direction for targeting KRAS-driven tumor metabolism and is expected to provide a potential new approach for the treatment of CCA (Lee D. S. et al., 2024). Here, KRAS is linked to cholangiocarcinoma.